WGS Utang-utang marang kapitalisasi buku GeneDx Holdings Corp.

GeneDx Corp (WGS) - logo korporat

GeneDx Holdings Corp. (WGS) is minimizing operational losses by focusing on high-margin sequencing, although it remains dependent on insurance reimbursement conditions. Monetization is based on the sale of Big Data licenses, where the asset value reflected in the pakistan chart is 0.72. Under the leadership of Jessica Dumichell, the business is implementing AI solutions for genome analysis, aiming to become a key tool in medical diagnostics.

WGS GeneDx Corp: Rasio utang marang nilai buku ing interval 28.04.2023 - 29.10.2026
Sampel barang GeneDx Corp

This ratio determines the issuer's solvency by comparing total credit obligations to the market value of equity to assess default risk and the efficiency of leverage. In the context of GeneDx Holdings Corp. (WGS) expanding through the acquisition of AI platforms and strategic alliances, the proportion of debt within the firm's balance sheet capitalization reflects the balance between the aggressive development of genomic diagnostics and the financial stability of its assets.

Pesaing wigati

Utang-utang marang kapitalisasi buku TEM (Tempus AI Inc)|Utang marang aset resik qiagen.com|Ionis - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku Repligen Corp|Avidity (RNA) - Rasio utang marang kapitalisasi buku|Rasio utang marang nilai buku CRSP|RARE (Ultragenyx Pharmaceutical) - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku beamtx.com BEAM|Utang-utang marang kapitalisasi buku SRPT|Twist Bioscience Inc - Rasio utang marang nilai buku|10x Genomics Corp - Utang marang nilai buku|NTLA: Rasio utang marang nilai buku|STOK: Utang marang nilai buku|Rasio utang marang aset resik BLFS (biolifesolutions.com)|WVE: Utang-utang marang kapitalisasi buku|Maze Therapeutics, Inc. - Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku Sionna Pharma|Utang-utang marang nilai buku Prime Medicine Bio PRME|Rasio utang marang kapitalisasi buku Taysha Gene Therapies (TSHA)|Rasio utang marang kapitalisasi buku QURE (uniqure.com)|Utang-utang marang kapitalisasi buku MGTX (MeiraGTx)|RGNX: Rasio utang marang nilai buku|Solid Bio - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik Ocugen Pharma OCGN|Pacific Biosciences (PACB) - Rasio utang marang kapitalisasi buku|Rasio utang marang nilai buku BNTC|DSGN (Design Therapeutics, Inc.) - Utang-utang marang kapitalisasi buku|RCKT - Utang marang aset resik|Rasio utang marang kapitalisasi buku 4D Molecular Therapeutics Inc (FDMT)|Utang-utang marang aset resik lexeotx.com|Korro Bio - Utang marang nilai buku|Rasio utang marang aset resik EDIT|Silence Therapeutics plc - Utang-utang marang kapitalisasi buku|ProQR Therapeutics N.V. (PRQR) - Utang marang nilai buku|codexis.com (CDXS) - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku Sangamo BioSciences (SGMO)|Rasio utang marang kapitalisasi buku Nautilus Biotechnology, Inc.|MGX: Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku Precision BioSciences, Inc. (DTIL)|GBIO: Rasio utang-utang marang kapitalisasi buku|Boundless Bio, Inc - Utang marang nilai buku|Utang-utang marang aset resik Exicure Inc. (XCUR)|IMNN: Utang marang nilai buku|Phio Pharmaceuticals (PHIO) - Utang marang nilai buku|MBIO: Utang-utang marang kapitalisasi buku|Utang marang aset resik TransCode Therapeutics, Inc. RNAZ|Rasio utang marang kapitalisasi buku Bionano Genomics Inc.|Applied DNA Corp (APDN) - Utang-utang marang aset resik|Utang-utang marang kapitalisasi buku BLUE|immunoprecise.com - Rasio utang marang nilai buku|Rasio utang marang kapitalisasi buku Omega Therapeutics, Inc. OMGA|OMIC: Rasio utang marang nilai buku|Regulus Therapeutics Inc - Utang-utang marang kapitalisasi buku|SYRS - Utang-utang marang kapitalisasi buku|TBIO: Utang-utang marang kapitalisasi buku|Utang marang aset resik traconpharma.com TCON|UBX (Unity Biotechnology, Inc.) - Utang-utang marang kapitalisasi buku